Cart
sales@molnova.com
Ebaresdax hydrochloride
CAS No. 1334385-87-3
Ebaresdax hydrochloride( —— )
Catalog No. M36451 CAS No. 1334385-87-3
Ebaresdax hydrochloride has analgesic activity and is used in the study of painful diabetic neuropathy caused by type I or type II diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 445 | Get Quote |
|
| 5MG | 686 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1398 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEbaresdax hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionEbaresdax hydrochloride has analgesic activity and is used in the study of painful diabetic neuropathy caused by type I or type II diabetes.
-
DescriptionEbaresdax (ACP-044) hydrochloride can inhibit peroxynitrite oxidation derived by SIN-1 and peroxynitrite mediated Cytotoxicity with IC50s of 3.7±0.80 and 0.13±0.02 uM, respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayProteasome/Ubiquitin
-
TargetEndogenous Metabolite
-
RecptorEndogenous Metabolite
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1334385-87-3
-
Formula Weight302.78
-
Molecular FormulaC12H15ClN2O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C1=N[C@H](C(O)=O)C(C)(C)S1)C2=C(O)C=CC=C2.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mannion, James C.; Dax, Scott L. Analgesic compounds, compositions, and uses thereof. WO2011112602A1.
molnova catalog
related products
-
4-Methylbiphenyl
4-Methylbiphenyl is an endogenous metabolite.
-
5-Aminovaleric acid
5-aminovalerate (or 5-aminopentanoic acid) is a lysine degradation product. It can be produced both endogenously or through bacterial catabolism of lysine.
-
Glucagon-Like Peptid...
Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently Glucagon-Like Peptide 2 is used as a potential therapeutic agent for the human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency.
